Discusses Updated Phase 1/2 Data for NGN-401 Gene Therapy in Rett Syndrome June 29, 2026 8:00 AM EDTCompany ParticipantsLina ...

When is it genuinely worth upgrading from a standard brushed system to an advanced brushless option? For product teams developing next-generation wearables, medical devices, and high-end consumer ...

Working directly with a premier Wholesale LRA and ERM Coin Vibration Motors Manufacturer ensures engineering teams get exact technical consultation and scalable production capacity. Choosing between a ...

Taysha Gene Therapies (TSHA) remains a Buy on strong TSHA-102 Rett data, FDA-aligned pivotal path, and cash to 2028—read the ...

The Cubs shortstop had himself a game.

The Industrial Internet of Things has made machines visible. It is now shifting the focus from collecting data to acting on ...

More than two decades since the Concorde supersonic airliner last took to the skies, NASA has been flying an experimental ...

South Korea’s benchmark Kospi has become the world’s most volatile major stock market as the AI boom collides with rising ...

Successfully completed an initial public offering on Nasdaq on May 14, 2026, issuing 80.5 million shares of Class A common stock, including the full exercise of the underwriters’ over-allotment option ...

Rivian provided flights from Los Angeles to Salt Lake City, Utah, and accommodation so Ars could drive the R2. Ars does not accept paid editorial content. This month, Rivian begins customer deliveries ...

After two weeks with Google’s Fitbit Air, I find it to be an impressive health tracker led by unique AI coaching, useful data insights and a reasonable price tag.

Sanofi's Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, ...